Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.

Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB.

Arthritis Rheumatol. 2019 Sep;71(9):1450-1459. doi: 10.1002/art.40911. Epub 2019 Aug 6.

2.

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.

Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R.

Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930.

3.

Dr. Charles-Schoeman and E. Bananis Reply.

Charles-Schoeman C, Bananis E.

J Rheumatol. 2018 Nov;45(11):1605. doi: 10.3899/jrheum.180489. Epub 2018 Nov 1. No abstract available.

PMID:
30385698
4.

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.

Bae S, Charles-Schoeman C.

Clin Rheumatol. 2018 Aug;37(8):2113-2123. doi: 10.1007/s10067-018-4174-3. Epub 2018 Jul 3.

PMID:
29971584
5.

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST.

Atherosclerosis. 2018 Aug;275:107-114. doi: 10.1016/j.atherosclerosis.2018.04.003. Epub 2018 Apr 17.

6.

Cardiac Transplantation in Dermatomyositis: A case report and literature review.

Bae S, Khanlou N, Charles-Schoeman C.

Hum Pathol (N Y). 2017 Jun;8:55-58. doi: 10.1016/j.ehpc.2017.03.005. Epub 2017 Mar 31.

7.

Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.

Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R.

J Rheumatol. 2018 Feb;45(2):177-187. doi: 10.3899/jrheum.170486. Epub 2017 Nov 15.

8.

High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis.

Charles-Schoeman C, Meriwether D, Lee YY, Shahbazian A, Reddy ST.

Clin Rheumatol. 2018 Mar;37(3):615-622. doi: 10.1007/s10067-017-3896-y. Epub 2017 Nov 11.

9.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.

Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

10.

Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.

Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST.

Arthritis Rheumatol. 2017 Jan;69(1):46-57. doi: 10.1002/art.39833.

11.

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.

Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, Geier J, Kwok K, Riese R.

Semin Arthritis Rheum. 2016 Dec;46(3):261-271. doi: 10.1016/j.semarthrit.2016.05.014. Epub 2016 Jun 2.

12.

Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.

Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R.

Semin Arthritis Rheum. 2016 Aug;46(1):71-80. doi: 10.1016/j.semarthrit.2016.03.004. Epub 2016 Mar 9. Review.

13.

Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL Jr, Curtis JR.

Arthritis Rheumatol. 2016 Mar;68(3):577-86. doi: 10.1002/art.39502.

14.

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.

Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R.

Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14. Erratum in: Ann Rheum Dis. 2017 Mar;76(3):611.

15.

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.

Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB.

Arthritis Rheumatol. 2015 Mar;67(3):616-25. doi: 10.1002/art.38974.

16.

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH.

Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.

17.

The heart in inflammatory myopathies.

Van Gelder H, Charles-Schoeman C.

Rheum Dis Clin North Am. 2014 Feb;40(1):1-10. doi: 10.1016/j.rdc.2013.10.002. Review.

PMID:
24268006
18.

Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis.

Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK, Taylor M, Ragavendra N, McMahon M, Elashoff D, Reddy ST.

Arthritis Rheum. 2013 Nov;65(11):2765-72. doi: 10.1002/art.38118.

19.

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR.

Arthritis Rheum. 2013 Jun;65(6):1430-8. doi: 10.1002/art.37916.

20.

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C; ORAL Step investigators.

Lancet. 2013 Feb 9;381(9865):451-60. doi: 10.1016/S0140-6736(12)61424-X. Epub 2013 Jan 5.

PMID:
23294500
21.

Cardiovascular disease and rheumatoid arthritis: an update.

Charles-Schoeman C.

Curr Rheumatol Rep. 2012 Oct;14(5):455-62. doi: 10.1007/s11926-012-0271-5. Review.

22.

Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey.

Charles-Schoeman C, Amjadi SS, Paulus HE; International Myositis Assessment and Clinical Studies Group.

Clin Rheumatol. 2012 Aug;31(8):1163-8. Epub 2012 Apr 21.

PMID:
22526479
23.

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.

Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST.

Ann Rheum Dis. 2012 Jul;71(7):1157-62. doi: 10.1136/annrheumdis-2011-200493. Epub 2012 Jan 20.

24.

Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis.

Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST.

Arthritis Rheum. 2012 Jun;64(6):1828-37. doi: 10.1002/art.34363. Epub 2012 Jan 9.

25.

Nicotinamide adenine dinucleotide tetrazolium reductase identifies microvasculature activation in muscle from adult patients with dermatomyositis.

Charles-Schoeman C, Verity MA.

J Rheumatol. 2012 Jan;39(1):94-9. doi: 10.3899/jrheum.110739. Epub 2011 Dec 15.

PMID:
22174214
26.

A biochemical fluorometric method for assessing the oxidative properties of HDL.

Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, Fogelman AM, Navab M, Yang OO.

J Lipid Res. 2011 Dec;52(12):2341-51. doi: 10.1194/jlr.D018937. Epub 2011 Sep 27.

27.

An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy.

Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE.

Rheumatol Int. 2012 Sep;32(9):2725-9. doi: 10.1007/s00296-011-2037-1. Epub 2011 Jul 30.

PMID:
21805175
28.

High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids.

McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH.

Ann Rheum Dis. 2011 Sep;70(9):1619-24. doi: 10.1136/ard.2010.142737. Epub 2011 Jun 13.

29.

Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST.

Circ J. 2011;75(7):1533-8. Epub 2011 May 28. Review.

30.

Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus.

Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, McMahon M.

Arthritis Care Res (Hoboken). 2010 Feb;62(2):258-65. doi: 10.1002/acr.20076.

31.

Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.

Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST.

Arthritis Rheum. 2009 Oct;60(10):2870-9. doi: 10.1002/art.24802.

32.

Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH.

Arthritis Rheum. 2009 Aug;60(8):2428-37. doi: 10.1002/art.24677.

33.

Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.

Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E.

Clin Immunol. 2008 May;127(2):234-44. doi: 10.1016/j.clim.2008.01.016. Epub 2008 Mar 12.

PMID:
18337176
34.

Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.

Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ.

J Rheumatol. 2007 Jul;34(7):1459-64. Epub 2007 Jun 1.

PMID:
17552046

Supplemental Content

Loading ...
Support Center